Hepatitis B

Sherlock's Diseases of the Liver and Biliary System, 12th Edition

Volumn , Issue , 2011, Pages 367-392

  Lok, Anna S F ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Antiviral therapy; Cirrhosis; Hepatitis B vaccine; Hepatitis B virus; Hepatocellular carcinoma

Indexed keywords

EID: 84888724335     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444341294.ch18     Document Type: Chapter

References (104)

1. Blumberg BS, Alter HJ, Visnich S. A 'new'antigen in leukemia sera. JAMA 1965; 191: 541-546.
2. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N. Engl. J. Med. 2004; 350: 1118-1129.
3. Fung SK, Lok AS. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 2004; 40: 790-792.
4. Norder H, Courouce AM, Coursaget P et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004; 47: 289-309.
5. Chotiyaputta W, Lok AS. Hepatitis B virus variants. Nat. Rev. Gastroenterol. Hepatol. 2009; 6: 453-462.
6. Carman WF, Hadziyannis S, McGarvey MJ et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989: 2: 588-591.
7. Yang HI, Yeh SH, Chen PJ et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J. Natl. Cancer Inst. 2008; 100: 1134-1143.
8. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 2006; 1: 23-61.
9. Ferrari C, Penna A, Bertoletti A et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J. Immunol. 1990; 145: 3442-3449.
10. Ferrari C, Missale G, Boni C et al. Immunopathogenesis of hepatitis B. J. Hepatol. 2003; 39(Suppl. 1): S36-42.
11. Ferrari C, Penna A, Bertoletti A et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J. Immunol. 1990; 145: 3442-3449.
12. Rehermann B, Lau D, Hoofnagle JH et al. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J. Clin Invest. 1996; 97: 1655-1665.
13. Maini MKB, Lee C, Larrubia CK et al. The role of virus-specific CD8(+)cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. 2000; 191: 1269-1280.
14. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepatol. 2004; 11: 97-107.
15. Mast EE, Margolis HS, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm. Rep. 2005; 54: 1-31.
16. Mast EE, Weinbaum CM, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm. Rep. 2006; 55: 1-33.
17. Weinbaum CM, Williams I, Mast EE et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep. 2008; 57: 1-20.
18. Bond WW, Favero MS, Petersen NJ et al. Survival of hepatitis B virus after drying and storage for one week. Lancet 1981; 1: 550-551.
19. Dodd RY. Current viral risks of blood and blood products. Ann. Med. 2000; 32: 469-474.
20. Roth WK, Weber M, Petersen D et al. NAT for HBV and anti-HBc testing increase blood safety. Transfusion 2002; 42: 869-875.
21. Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 2008; 48: 1001-1026.
22. Wachs ME, Amend WJ, Ascher NL et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-)organ donors. Transplantation 1995; 59: 230-234.
23. Dickson RC, Everhart JE, Lake JR et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113: 1668-1674.
24. Harpaz R, Von Seidlein L, Averhoff FM et al. Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. N. Engl. J. Med. 1996; 334: 549-554.
25. Gunson RN, Shouval D, Roggendorf M et al. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J. Clin. Virol. 2003; 27: 213-230.
26. Wong VC, Ip HM, Reesink HW et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet 1984; 1: 921-926.
27. Wiseman E, Fraser MA, Holden S et al. Perinatal transmission of hepatitis B virus: an Australian experience. MJA 2009; 190: 489-492.
28. Ni YH, Huang LM, Chang MH et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 2007; 132: 1287-1293.
29. Chang MH, You SL, Chen CJ et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl. Cancer Inst. 2009; 101: 1348-1355.
30. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 1997; 336: 1855-1859.
31. Su FH, Cheng SH, Li CY et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 2007; 25: 8085-8090.
32. McMahon BJ, Dentinger CM, Bruden D et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J. Infect. Dis. 2009; 200: 1390-1396.
33. Zanetti AR, Mariano A, Romano L et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366: 1379-1384.
34. Demicheli V, Rivetti A, Di Pietrantonj C et al. Hepatitis B vaccination and multiple sclerosis: evidence from a systematic review. J. Viral. Hepat. 2003; 10: 343-344.
35. Carman WF, Zanetti AR, Karayiannis P et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336: 325-329.
36. Kumar M, Sarin SK, Hissar S et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008; 134: 1376-1384.
37. Lai M, Hyatt BJ, Nasser I et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J. Hepatol. 2007; 47: 760-767.
38. Nguyen MH, Garcia RT, Trinh HN et al. Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels. Am. J. Gastroenterol. 2009; 104: 2206-2213.
39. Lok AS. Hepatitis B: liver fibrosis and hepatocellular carcinoma. Gastroenterol. Clin. Biol. 2009; 33: 911-915.
40. Guillevin L, Lhote F, Gayraud M et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996; 75: 17-28.
41. Lai KN, Lai FM, Chan KW et al. The clinico-pathologic features of hepatitis B virus-associated glomerulonephritis. Q. J. Med. 1987; 63: 323-333.
42. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43: S173-181.
43. Rehermann B, Chang KM, McHutchinson J et al. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J. Virol. 1996; 70: 7092-7102.
44. Chu CM, Hung SJ, Lin J et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am. J. Med. 2004; 116: 829-834.
45. Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J. Viral. Hepat. 2007; 14: 147-152.
46. Liaw YF, Chu CM, Su IJ et al. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983; 84: 216-219.
47. Lok AS, Lai CL, Wu PC et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92: 1839-1843.
48. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122: 1756-1762.
49. Manno M, Camma C, Schepis F et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004; 127: 756-763.
50. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45: 1187-1192.
51. Ahn SH, Park YN, Park JY et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J. Hepatol. 2005; 42: 188-194.
52. Yuen MF, Wong DK, Fung J et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 1192-1199.
53. Chen YC, Sheen IS, Chu CM et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123: 1084-1089.
54. Raimondo G, Allain JP, Brunetto MR et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol. 2008; 49: 652-657.
55. Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med. 2002; 347: 168-174.
56. Iloeje U, Yang H, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.
57. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
58. Yu MW, Yeh SH, Chen PJ et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J. Natl. Cancer Inst. 2005; 97: 265-272.
59. Sorrell MF, Belongia EA, Costa J et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann. Intern. Med. 2009; 150: 104-110.
60. European Association For The Study Of The Liver. EASL Clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 2009; 50: 227-242.
61. Liaw YF, Leung N, Kao JH et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2008; 2: 263-283.
62. Lok AS, McMahon BJ. Practice guidelines: chronic hepatitis B. Hepatology 2007; 45: 507-539.
63. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
64. Degertekin B, Lok AS. Indications for therapy in hepatitis B. Hepatology 2009; 49: S129-137.
65. Fontana RJ, Hann HW, Perrillo RP et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719-727.
66. Yao FY, Terrault NA, Freise C et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34: 411-416.
67. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-1531.
68. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49: S156-165.
69. Loomba R, Rowley A, Wesley R et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann. Intern. Med. 2008; 148: 519-528.
70. Lok AS, Ma OC, Lau JY. Interferon alfa therapy in patients with chronic hepatitis B virus infection. Effects on hepatitis B virus DNA in the liver. Gastroenterology 1991; 100: 756-761.
71. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49: S185-195.
72. Chotiyaputta W, Lok AS. Role of antiviral therapy in the prevention of perinatal transmission of hepatitis B virus infection. J. Viral. Hepatol. 2009; 16: 91-93.
73. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005; 352: 2682-2695.
74. Janssen HL, van Zonneveld M, Senturk H et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-129.
75. Buster EH, Flink HJ, Cakaloglu Y et al. Sustained HBeAg and HBsAg Loss after Long-Term Follow-up of HBeAg-Positive Patients Treated with Peginterferon a-2b. Gastroenterology 2008; 135: 459-467.
76. Marcellin P, Lau GK, Bonino F et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2004; 351: 1206-1217.
77. Marcellin P, Bonino F, Lau GK et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-2179.
78. Perrillo RP, Lai CL, Liaw YF et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186-194.
79. Perrillo R, Tamburro C, Regenstein F et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109: 908-916.
80. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999; 341: 1256-1263.
81. Lai C, Chien R, Leung N et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 1998; 339: 61-68.
82. Marcellin P, Chang T, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 2003; 348: 808-816.
83. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1001-1010.
84. Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007; 357: 2576-2588.
85. Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 2008; 359: 2442-2455.
86. Marcellin P, Chang TT, Lim SG et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008; 48: 750-758.
87. Gish RG, Lok AS, Chang TT et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-1444.
88. Liaw YF, Gane E, Leung N et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495.
89. Wang Y, Thongsawat S, Gane EJ et al. Efficacy and safety outcomes after 4 years of telbivudine treatment in patients with chronic hepatitis B (CHB). Hepatology 2009; 50: 533A.
90. Heathcote EJ, Gane EJ, De Man RA et al. Three years of tenofovir disoproxil (TDF) treatment in HBeAg-positive patients (HBeAg +)with chronic hepatitis B (Study 103), preliminary analysis. Hepatology 2009; 50: 533A-534A.
91. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 2003; 348: 800-807.
92. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1011-1020.
93. Hadziyannis S, Tassopoulos N, Heathcote E et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751.
94. Marcellin P, Buti M, Krastev Z et al. Three years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (Study 102); preliminary analysis. Hepatology 2009; 50: 532A-533A.
95. Lok AS, Zoulim F, Locarnini S et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-265.
96. Tenney DJ, Rose RE, Baldick CJ et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514.
97. Amini-Bavil-Olyaee S, Herbers U, Sheldon J et al. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009; 49: 1158-1165.
98. Yim HJ, Hussain M, Liu Y et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703-712.
99. Fleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J. Hepatol. 2009; 51: 787-791.
100. Lange CM, Bojunga J, Hofmann WP et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001-2006.
101. Lai CL, Leung N, Teo EK et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-536.
102. Sung JJ, Lai JY, Zeuzem S et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J. Hepatol. 2008; 48: 728-735.
103. Hadziyannis S, Sevastianos V, Rapti I. Outcome of HBeAg-negative chronic hepatitis B (CHG) 5 years after discontinuation of long term adefovir dipivoxil (ADV) treatment. J. Hepatol. 2009; 50: S9, Abstract 18.
104. Yuen MF, Sablon E, Hui CH et al. Factors preceding hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34: 785-791.